Tumor cellularity beyond the visible in soft tissue sarcomas: Results of an ADC-based, single center, and preliminary radiomics study.
magnetic resonance
metastasis
radiomics
soft tissue sarcoma
tumor grade
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
02
2022
accepted:
20
09
2022
entrez:
28
10
2022
pubmed:
29
10
2022
medline:
29
10
2022
Statut:
epublish
Résumé
Soft tissue sarcomas represent approximately 1% of all malignancies, and diagnostic radiology plays a significant role in the overall management of this rare group of tumors. Recently, quantitative imaging and, in particular, radiomics demonstrated to provide significant novel information, for instance, in terms of prognosis and grading. The aim of this study was to evaluate the prognostic role of radiomic variables extracted from apparent diffusion coefficient (ADC) maps collected at diagnosis in patients with soft tissue sarcomas in terms of overall survival and metastatic spread as well as to assess the relationship between radiomics and the tumor grade. Patients with histologically proven soft tissue sarcomas treated in our tertiary center from 2016 to 2019 who underwent an Magnetic Resonance (MR) scan at diagnosis including diffusion-weighted imaging were included in this retrospective institution review board-approved study. Each primary lesion was segmented using the b50 images; the volumetric region of interest was then applied on the ADC map. A total of 33 radiomic features were extracted, and highly correlating features were selected by factor analysis. In the case of feature/s showing statistically significant results, the diagnostic accuracy was computed. The Spearman correlation coefficient was used to evaluate the relationship between the tumor grade and radiomic features selected by factor analysis. All analyses were performed applying p<0.05 as a significant level. A total of 36 patients matched the inclusion criteria (15 women; mean age 58.9 ± 15 years old). The most frequent histotype was myxofibrosarcoma (16.6%), and most of the patients were affected by high-grade lesions (77.7%). Seven patients had pulmonary metastases, and, altogether, eight were deceased. Only the feature Imc1 turned out to be a predictor of metastatic spread (p=0.045 after Bonferroni correction) with 76.7% accuracy. The value -0.16 showed 73.3% sensitivity and 71.4% specificity, and patients with metastases showed lower values (mean Imc1 of metastatic patients -0.31). None of the examined variables was a predictor of the overall outcome (p>0.05, each). A moderate statistically significant correlation emerged only between Imc1 and the tumor grade (r=0.457, p=0.005). In conclusion, the radiomic feature Imc1 acts as a predictor of metastatic spread in patients with soft tissue sarcomas and correlates with the tumor grade.
Identifiants
pubmed: 36303833
doi: 10.3389/fonc.2022.879553
pmc: PMC9592822
doi:
Types de publication
Journal Article
Langues
eng
Pagination
879553Informations de copyright
Copyright © 2022 Giraudo, Fichera, Del Fiore, Mocellin, Brunello, Rastrelli and Stramare.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Radiographics. 2014 Sep-Oct;34(5):1163-77
pubmed: 25208274
Radiol Oncol. 2019 Sep 24;53(3):300-306
pubmed: 31553702
J Magn Reson Imaging. 2019 Dec;50(6):1773-1788
pubmed: 30980697
J Digit Imaging. 2021 Oct;34(5):1146-1155
pubmed: 34545474
Radiographics. 2008 Nov-Dec;28(7):2069-86
pubmed: 19001660
Cancer Imaging. 2021 Jan 6;21(1):1
pubmed: 33407884
AJR Am J Roentgenol. 2012 Jan;198(1):162-72
pubmed: 22194493
J Magn Reson Imaging. 2020 Jul;52(1):282-297
pubmed: 31922323
Radiology. 2016 Mar;278(3):831-40
pubmed: 26390048
Phys Med Biol. 2015 Jul 21;60(14):5471-96
pubmed: 26119045
Sci Rep. 2021 Jan 21;11(1):1879
pubmed: 33479398
Clin Radiol. 2020 Oct;75(10):798.e13-798.e22
pubmed: 32723501
Radiology. 2014 May;271(2):499-511
pubmed: 24495264
Eur Radiol. 2020 Feb;30(2):914-924
pubmed: 31630234
AJR Am J Roentgenol. 2020 Oct;215(4):963-969
pubmed: 32755226
Curr Oncol Rep. 2000 Nov;2(6):487-90
pubmed: 11122882
Radiol Med. 2021 Jun;126(6):878-885
pubmed: 33683542
Skeletal Radiol. 2020 Nov;49(11):1829-1838
pubmed: 32519183
Eur Radiol. 2020 Aug;30(8):4595-4605
pubmed: 32222795
Cancers (Basel). 2020 Jun 08;12(6):
pubmed: 32521645
J Magn Reson Imaging. 2018 May;47(5):1217-1226
pubmed: 29086453
Eur Radiol. 2020 May;30(5):2413-2424
pubmed: 31953663
J Magn Reson Imaging. 2018 Mar;47(3):829-840
pubmed: 28653477
Diagnostics (Basel). 2021 Sep 09;11(9):
pubmed: 34573991
Phys Med Biol. 2020 Aug 27;65(17):175006
pubmed: 32554891
Sci Rep. 2021 Oct 11;11(1):20133
pubmed: 34635786
Clin Radiol. 2021 Feb;76(2):158.e19-158.e25
pubmed: 33293024
J Magn Reson Imaging. 2019 Aug;50(2):497-510
pubmed: 30569552
Cancers (Basel). 2021 Aug 10;13(16):
pubmed: 34439186
Sci Rep. 2019 Mar 18;9(1):4800
pubmed: 30886309
J Natl Compr Canc Netw. 2018 May;16(5):536-563
pubmed: 29752328